Australia markets closed

Inozyme Pharma, Inc. (INZY)

NasdaqGS - NasdaqGS Delayed price. Currency in USD
Add to watchlist
4.7400-0.1100 (-2.27%)
At close: 04:00PM EDT
4.8500 +0.11 (+2.32%)
After hours: 06:32PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 293.20M
Enterprise value 173.68M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)2.47
Enterprise value/revenue N/A
Enterprise value/EBITDA 0.21

Trading information

Stock price history

Beta (5Y monthly) 1.55
52-week change 3-17.42%
S&P500 52-week change 323.76%
52-week high 37.7950
52-week low 32.6890
50-day moving average 34.7494
200-day moving average 34.6234

Share statistics

Avg vol (3-month) 3583.61k
Avg vol (10-day) 3259.47k
Shares outstanding 561.86M
Implied shares outstanding 661.86M
Float 837.91M
% held by insiders 10.52%
% held by institutions 192.78%
Shares short (15 May 2024) 42.69M
Short ratio (15 May 2024) 45.16
Short % of float (15 May 2024) 44.72%
Short % of shares outstanding (15 May 2024) 44.35%
Shares short (prior month 15 Apr 2024) 43.15M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-32.56%
Return on equity (ttm)-69.41%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -82.21M
Net income avi to common (ttm)-77.11M
Diluted EPS (ttm)-1.3500
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)166.15M
Total cash per share (mrq)2.69
Total debt (mrq)46.63M
Total debt/equity (mrq)39.24%
Current ratio (mrq)14.05
Book value per share (mrq)1.92

Cash flow statement

Operating cash flow (ttm)-77.44M
Levered free cash flow (ttm)-52.53M